CanVirex

ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need. ImmVirX was founded in late 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration – potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer. The ImmVirX team comprises key directors, executives and scientific staff from Viralytics. ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations. ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at The @Bell_Potter Healthcare Conference 2023 is now available. Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia. Leveraging our leadership and experience in oncolytic viral therapies, we are actively progressing clinical trials, based on a body of pre-clinical and manufacturing data developed since operations commenced in 2020.

Virometix AG is a privately held Swiss biotechnology company whose purpose is the discovery and development of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer. At Virometix, we believe that fully synthetic vaccines that generate selective immune responses against synthetic antigens mimicking critically important native epitopes on pathogens provide several advantages over traditional vaccine design. Virometix AG is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. We are developing a portfolio of products highlighted by a serotype-independent vaccine candidate against Streptococcus pneumoniae, a first-in-class vaccine candidate for Respiratory Syncytial Virus (RSV) and and Coronaviruses prophylactic approaches. The company is a spinout from the department of organic chemistry at the University of Zurich which provided the expertise in structural biology and synthetic chemistry that laid the foundation for our synthetic nanoparticle platform technology. Our present focus is the generation of a novel, peptide antigen-based vaccine with the potential to provide serotype-independent protective immunity against infection caused by Streptococcus pneumoniae. These advantages include the safety, simplicity and efficiency of a fully synthetic manufacturing process that avoids the use of biological materials. Chief Executive OfficerAnna Sumeray has over 25 years of experience in the life sciences sector with a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.Anna’s diverse experiences include the building of a successful European biotech business for a US-based company from the ground up and the management of Novartis’s oncology businesses in Finland and Germany.

Welcome to FinVector, a leading cGMP manufacturer of viral-based products with a strong commitment to restoring hope, purpose and a true sense of belonging for those living with chronic health conditions. FinVector has firmly established itself as a beacon of innovation in the cancer drug industry, gaining international recognition as a leader in Viral-Based Gene Therapy product manufacturing. Presently, FinVector produces a groundbreaking treatment for Non-Muscle Invasive Bladder Cancer, offering meaningful hope to countless patients worldwide. Everything we do, we are driven by our commitment to improving the lives of people with chronic health conditions. FinVector is a dedicated partner in the fight against cancer. We are immensely proud to have them on board, and we invite you to join us in this vital fight. We are a cGMP manufacturer of viral-based gene therapy products that improve the lives of people battling chronic health conditions such as bladder cancer. Explore how our dedicated team pioneers viral-based gene therapy manufacturing technology to improve the lives of people with chronic health conditions.

Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs. Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

Viravaxx AG is a privately held company based in Vienna, Austria. One flagship project is a vaccine against Hepatitis B. The newly developed vaccine is a step towards the therapeutic as well as prophylactic use of vaccination against chronic hepatitis B.

ViraTherapeutics is a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. ViraTherapeutics specializes in the development of highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future. We are committed to developing new treatments for people living with cancer and improving their quality of life. Take your chance and check our recent job offers.